Market closedNon-fractional
Design Therapeutics/DSGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Ticker
DSGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Carlsbad, United States
Employees
57
Website
www.designtx.com
DSGN Metrics
BasicAdvanced
$193M
Market cap
-
P/E ratio
-$1.05
EPS
1.88
Beta
-
Dividend rate
Price and volume
Market cap
$193M
Beta
1.88
Financial strength
Current ratio
38.608
Quick ratio
38.157
Long term debt to equity
0.795
Total debt to equity
1.068
Management effectiveness
Return on assets (TTM)
-14.69%
Return on equity (TTM)
-20.15%
Valuation
Price to book
0.72
Price to tangible book (TTM)
0.72
Price to free cash flow (TTM)
-3.559
Growth
Earnings per share change (TTM)
-15.87%
3-year earnings per share growth
9.04%
What the Analysts think about DSGN
Analyst Ratings
Majority rating from 3 analysts.
DSGN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
-5.93%
Profit margin
0.00%
NaN%
DSGN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.28
-$0.21
-$0.20
-
Expected
-$0.40
-$0.41
-$0.31
-$0.26
-$0.23
Surprise
-9.43%
-31.46%
-32.20%
-24.05%
-
DSGN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Design Therapeutics stock?
Design Therapeutics (DSGN) has a market cap of $193M as of July 06, 2024.
What is the P/E ratio for Design Therapeutics stock?
The price to earnings (P/E) ratio for Design Therapeutics (DSGN) stock is 0 as of July 06, 2024.
Does Design Therapeutics stock pay dividends?
No, Design Therapeutics (DSGN) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Design Therapeutics dividend payment date?
Design Therapeutics (DSGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Design Therapeutics?
Design Therapeutics (DSGN) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Design Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.